Loading clinical trials...
Loading clinical trials...
The purpose of this study is to evaluate the safety and efficacy of HepaSphere interventional therapy using digital subtraction angiography（DSA）for lung cancer.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Fuda Cancer Hospital, Guangzhou
NCT06689488 · Lung Cancer
NCT06500481 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, and more
NCT00899405 · Lung Cancer
NCT07668037 · Non-Small Cell Carcinoma of Lung, Immunotherapy, and more
NCT02682667 · Multiple Myeloma, Lymphoma, Non-Hodgkin, and more
Central laboratory in Fuda cancer hospital
Guangzhou, Guangdong
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions